Drug Overview

Daporinad is an investigational targeted therapy drug studied for its unique ability to starve cancer cells of the energy they need to grow and spread rapidly. As a “smart drug” classified as a NAMPT inhibitor, it precisely blocks a key enzyme in the cell’s energy production pathway called nicotinamide phosphoribosyltransferase (NAMPT), disrupting tumor metabolism while potentially sparing healthy cells that have backup energy routes. This comprehensive guide delivers clear, trustworthy information for international patients in the US, Europe, and beyond, as well as oncology professionals seeking insights into its trial history, metabolic mechanism, and potential in combination therapies. Also known by research code names like FK866 or APO866, daporinad targets the NAD+ salvage pathway, a metabolic shortcut many aggressive cancers exploit to thrive under stress, offering a novel strategy distinct from traditional chemotherapy or targeted kinase inhibitors.

For patients battling advanced solid tumors or lymphomas, daporinad represents an exciting area of metabolic oncology research, particularly in settings where tumors resist standard treatments. Although clinical development paused after Phase I/II trials due to challenges with efficacy, toxicity, and resistance mechanisms, its precise action on cancer’s energy vulnerabilities continues to fuel preclinical studies and inspire next-generation NAD+ pathway blockers.

Generic name: Daporinad (also called FK866 or APO866).
US Brand names: None.
Drug Class: Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor; targeted metabolic therapy.
Route of Administration: Intravenous (IV) infusion.
FDA Approval Status: Not FDA-approved; discontinued in clinical development after Phase I/II trials due to limited single-agent activity and safety concerns.

What Is It and How Does It Work? (Mechanism of Action)

Daporinad works as a targeted therapy by attacking cancer cells at their metabolic core, cutting off the energy supply they desperately need for uncontrolled growth, DNA repair, and survival. Unlike normal cells, which produce energy through balanced pathways, cancer cells guzzle nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in over 400 biochemical reactions, including glycolysis, fatty acid oxidation, and gene regulation. Tumors often over-rely on the NAD+ “salvage” pathway to recycle NAD+ quickly under low-oxygen or nutrient-poor conditions.

At the molecular level, daporinad acts as a highly potent competitive inhibitor of NAMPT, the gatekeeper enzyme of this salvage pathway (IC50 approximately 0.09 nM). NAMPT catalyzes the conversion of nicotinamide (a vitamin B3 breakdown product) and 5-phosphoribosyl-1-pyrophosphate (PRPP) into nicotinamide mononucleotide (NMN), the direct precursor to NAD+. By binding tightly to NAMPT’s active site, daporinad halts NMN production, causing intracellular NAD+ levels to plummet by 70-90% within 24-48 hours in sensitive cells.

This NAD+ depletion unleashes a domino effect tailored to cancer vulnerabilities. Glycolysis grinds to a halt without NAD+ to regenerate during the glyceraldehyde-3-phosphate dehydrogenase step, slashing ATP output. DNA repair falters as poly(ADP-ribose) polymerases (PARPs) starve for NAD+, amplifying replication fork collapse and double-strand breaks. Sirtuins (SIRT1-7), NAD+-dependent deacetylases that silence tumor suppressors like p53 and FOXO3, lose activity, freeing these proteins to trigger cell cycle arrest and apoptosis. Mitochondria swell with reactive oxygen species (ROS) from stalled electron transport, activating AMPK (energy crisis sensor) and ultimately caspases-3, -7, and -9 for programmed cell death. Additionally, daporinad curbs angiogenesis by downregulating vascular endothelial growth factor (VEGF) and inhibits metastasis by disrupting metabolic reprogramming. Normal cells resist better via the de novo NAD+ synthesis from tryptophan/niacin, highlighting daporinad’s selective “metabolic Achilles’ heel” punch against tumors.

FDA-Approved Clinical Indications

Daporinad has no FDA-approved indications, remaining confined to research after early-phase setbacks.

Oncological uses (studied in trials):

Advanced solid tumors, including melanoma, glioblastoma, ovarian, prostate, and colorectal cancers.
Hematologic malignancies such as cutaneous T-cell lymphoma (CTCL), B-cell chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.
Small cell lung cancer and other NAD+-addicted neuroendocrine tumors.

Non-oncological uses (if any):

None identified.

Dosage and Administration Protocols

In clinical trials, daporinad required continuous IV infusion over multiple days to sustain NAMPT blockade, given its short plasma half-life and tissue-specific action. Common regimens used 28-day cycles with built-in recovery periods to mitigate blood count drops.

Specification	Details
Standard Dose (from trials)	0.035-0.075 mg/m²/hour continuous IV infusion
Frequency	Days 1-4 (96 hours) every 28 days; alternatives: weekly shorter infusions
Infusion Time	Continuous over 96 hours; central line preferred
Renal Insufficiency (Mild/Moderate)	No adjustment; monitor creatinine clearance weekly
Severe Renal Impairment	Limited data; initiate at lowest dose, avoid if CrCl <30 mL/min
Hepatic Insufficiency (Child-Pugh A)	No adjustment; baseline LFTs required
Moderate/Severe (Child-Pugh B/C)	Reduce dose by 25-50%; contraindicated in C
Dose Modifications	Reduce for grade 3 thrombocytopenia; premedicate with antiemetics/steroids

Therapeutic drug monitoring tracked NAD+ proxies like lactate; dose-limiting toxicity often occurred by cycle 2.

Clinical Efficacy and Research Results

Recent trials (2020-2025) are scarce, as daporinad’s program stalled pre-2015 amid modest monotherapy results, but preclinical combo work persists. Early Phase I/II studies across advanced refractory cancers (n>100) achieved stable disease in 20-40% of patients lasting 2-6 months, with objective response rates below 10%. In CTCL cohorts (small n=15), partial responses or prolonged stabilization occurred in about 25%, correlating with high tumor NAMPT expression.

Preclinical models vividly illustrate potential: glioblastoma xenografts shrank 60-80% via NAD+ crash, sensitizing to temozolomide; ovarian lines showed 70% apoptosis and doubled cisplatin efficacy. CLL cells underwent 70-90% cell death in vitro, sparing normal lymphocytes. Lung cancer combos with PARP inhibitors extended survival 2-3 fold in mice. Median progression-free survival in human monotherapy hovered at 3-5 months, limited by NAPRT1-mediated resistance (backup NAD+ path upregulated in 30-50% tumors). No Phase III data or overall survival benefits emerged, redirecting interest to synergistic pairs like immunotherapy or chemotherapy.

Safety Profile and Side Effects

Daporinad’s profile stems from NAD+ loss in bone marrow and gut stem cells, mimicking nutritional stress.

Common Side Effects (>10%)

Thrombocytopenia (low platelets causing bruising/bleeding: 50-70%).
Neutropenia (infection risk from low white cells: 30-50%).
Fatigue and weakness (40-60%).
Nausea, vomiting, diarrhea (30-50%).
Anemia (low red cells, tiredness: 20-40%).

Serious Adverse Events

Life-threatening hemorrhage (10-20% from profound thrombocytopenia).
Sepsis or prolonged neutropenia (10-15%).
Rare gastrointestinal perforation/ileus (<5%).

No Black Box Warning issued.

Management Strategies:

Thrombocytopenia: Platelet transfusions for counts <10,000/µL or bleeding; withhold infusion until >50,000/µL, restart 25% lower.
Neutropenia: Prophylactic G-CSF (filgrastim 5 mcg/kg/day); delay cycle until ANC >1,000/mm³.
GI upset: Tiered antiemetics (ondansetron 8 mg IV, then aprepitant); BRAT diet, IV hydration.
Twice-weekly CBC differentials; weekly LFTs/electrolytes.
Emergency for fever >101°F, black/tarry stools, uncontrolled bleeding, or dizziness—hospitalize with cultures/transfusions.

Research Areas

Daporinad fuels excitement in combos with immunotherapies or PARP inhibitors, as NAD+ starvation heightens tumor DNA damage, PD-L1 expression, and T-cell infiltration, amplifying checkpoint blockade or CAR-T responses in preclinical resistant models.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

Baseline complete blood count (CBC) with differential/platelets.
Liver function tests (ALT/AST/bilirubin), kidney panel, coagulation (PT/INR).
Nutritional assessment (prealbumin, vitamin B3 levels).

Precautions during treatment:

Mandatory indwelling catheter for continuous infusion.
Prophylactic antiemetics and growth factors from day 1.
Effective contraception (mutagenic/teratogenic potential).

“Do’s and Don’ts” list:

DO report easy bruising, fever, chills, or black stools immediately to your care team.
DO maintain strict hygiene; eat soft, bland foods like bananas/rice; drink 2-3 liters water daily.
DO attend all blood draws and infusion checks without fail.
DON’T take aspirin, ibuprofen, or NSAIDs—increases bleeding risk dramatically.
DON’T ignore fatigue; rest but stay lightly active if possible.
DON’T consume alcohol or unapproved supplements/herbs.

Legal Disclaimer

This guide serves educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Daporinad remains strictly experimental and unavailable outside research protocols. Consult your oncologist for personalized evaluations, trial eligibility, or alternative therapies. Always adhere to guidance from licensed healthcare professionals.